Psoriasis Drugs Market Estimated To Reach $21.11 Billion By 2022: Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting.

According to report published by Grand View Research,“Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 – 2022”, published by Grand View Research, Inc.,The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Key Takeaways from the report:

• Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability

• TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors

• Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs

• The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services

• Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace

• Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

 Browse More Reports in Pharmaceuticals Industry:

• Cervical Cancer Treatment Market – Increased disease prevalence, proactive government initiatives, and advent of targeted therapies are the major factors contributing to the cervical cancer treatment market expansion.
• Antibiotic Resistance Market – High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the antibiotic resistance market.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Grand View Research has segmented the global psoriasis drugs market based on therapeutic class, treatment, and region:

Therapeutic Class Outlook (Revenue, USD Million, 2016 – 2022)

• Tumor Necrosis Factor Inhibitor

• Interleukin Inhibitors

• Others

Treatment Outlook (Revenue, USD Million, 2016 – 2022)

• Topicals

• Systemic

• Biologics

Regional Outlook (Revenue, USD Million, 2016 – 2022)

• U.S.

• U.K.

• Germany

• Spain

• France

• Italy

• Japan

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grad View Research, Inc.

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information: www.grandviewresearch.com

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market